PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34183434-2 2021 The mu-opioid receptor (MOPr) partial agonist buprenorphine, alone or in combination with naltrexone, has been shown to reduce cocaine positive urine tests and cocaine seeking in rodents. Buprenorphine 46-59 opioid receptor, mu 1 Mus musculus 4-22 34183434-2 2021 The mu-opioid receptor (MOPr) partial agonist buprenorphine, alone or in combination with naltrexone, has been shown to reduce cocaine positive urine tests and cocaine seeking in rodents. Buprenorphine 46-59 opioid receptor, mu 1 Mus musculus 24-28 34183434-5 2021 Thus, we hypothesized that a buprenorphine derivative that exhibits antagonist activity at MOPr and KOPr with enhanced agonist activity at the NOPr could provide a more effective treatment. Buprenorphine 29-42 opioid receptor, mu 1 Mus musculus 91-95 34183434-12 2021 The findings support the development of buprenorphine analogues lacking MOPr agonism with increased NOPr agonism for relapse prevention to cocaine addiction. Buprenorphine 40-53 opioid receptor, mu 1 Mus musculus 72-76 35620644-17 2022 BPN normalized MOR expression in both males and females. Buprenorphine 0-3 opioid receptor, mu 1 Mus musculus 15-18 27818236-5 2017 We found that behavioral responses to BPN in the NIH test were blocked in Oprm1-/- mice, but not in Oprk1-/- mice. Buprenorphine 38-41 opioid receptor, mu 1 Mus musculus 74-79 29127441-2 2018 The micro-opioid receptor (MOP-r) gene, Oprm1, resides at the proximal end of Chr 10, and buprenorphine reduces MA intake in MAHDR mice. Buprenorphine 90-103 opioid receptor, mu 1 Mus musculus 4-25 29127441-2 2018 The micro-opioid receptor (MOP-r) gene, Oprm1, resides at the proximal end of Chr 10, and buprenorphine reduces MA intake in MAHDR mice. Buprenorphine 90-103 opioid receptor, mu 1 Mus musculus 27-32 28188737-0 2017 Genetic variation in the behavioral effects of buprenorphine in female mice derived from a murine model of the OPRM1 A118G polymorphism. Buprenorphine 47-60 opioid receptor, mu 1 Mus musculus 111-116 28188737-2 2017 To date few studies have explored the potential impact of the OPRM1 A118G polymorphism on the pharmacological effects of buprenorphine (BPN), a potent MOR partial agonist and kappa opioid receptor antagonist, which is approved by the FDA for the treatment of opioid addiction and chronic pain. Buprenorphine 121-134 opioid receptor, mu 1 Mus musculus 62-67 28188737-3 2017 The goal of these studies was to determine whether the MOR-mediated behavioral effects of BPN were altered in the Oprm1 A112G mouse model of the human OPRM1 A118G SNP. Buprenorphine 90-93 opioid receptor, mu 1 Mus musculus 55-58 28188737-9 2017 These studies demonstrate the ability of the Oprm1 A112G SNP to attenuate the analgesic, anxiolytic and hyperlocomotor effects of BPN. Buprenorphine 130-133 opioid receptor, mu 1 Mus musculus 45-50 28188737-10 2017 Overall, these data suggest that the OPRM1 A118G SNP will significantly impact the clinical efficacy of BPN in its therapeutic applications. Buprenorphine 104-107 opioid receptor, mu 1 Mus musculus 37-42 27818236-1 2017 Buprenorphine (BPN), a mixed opioid drug with high affinity for mu (MOR) and kappa (KOR) opioid receptors, has been shown to produce behavioral responses in rodents that are similar to those of antidepressant and anxiolytic drugs. Buprenorphine 0-13 opioid receptor, mu 1 Mus musculus 68-71 27818236-1 2017 Buprenorphine (BPN), a mixed opioid drug with high affinity for mu (MOR) and kappa (KOR) opioid receptors, has been shown to produce behavioral responses in rodents that are similar to those of antidepressant and anxiolytic drugs. Buprenorphine 15-18 opioid receptor, mu 1 Mus musculus 68-71 27818236-8 2017 Moreover, antinociceptive studies revealed persistence of the MOR antagonist properties of BPN at 24h post-administration, the period of behavioral reactivity. Buprenorphine 91-94 opioid receptor, mu 1 Mus musculus 62-65 26979295-6 2016 In contrast, BPN reduced immobility in MOR and DOR knockout mice and in mice pretreated with the ORL-1 antagonist JTC-801. Buprenorphine 13-16 opioid receptor, mu 1 Mus musculus 39-42 25521224-9 2015 CONCLUSIONS AND IMPLICATIONS: Signalling to AC and ERK via the mutant MOPr-A6V was decreased for many opioids, including the clinically significant drugs morphine, buprenorphine and fentanyl, as well endogenous opioids. Buprenorphine 164-177 opioid receptor, mu 1 Mus musculus 70-78 19713488-2 2009 Buprenorphine, a high-affinity partial MOP receptor agonist also binds to NOP receptors with 80 nM affinity. Buprenorphine 0-13 opioid receptor, mu 1 Mus musculus 39-51 19713488-9 2009 These results further support the hypothesis that activation of NOP receptors can lead to attenuation of MOP receptor-mediated antinociception elicited by mixed NOP/MOP receptor compounds such as buprenorphine, SR16435, and SR16507 and that, although buprenorphine has low efficacy in vitro, it has significant NOP receptor agonist activity in vivo. Buprenorphine 196-209 opioid receptor, mu 1 Mus musculus 105-117 19713488-9 2009 These results further support the hypothesis that activation of NOP receptors can lead to attenuation of MOP receptor-mediated antinociception elicited by mixed NOP/MOP receptor compounds such as buprenorphine, SR16435, and SR16507 and that, although buprenorphine has low efficacy in vitro, it has significant NOP receptor agonist activity in vivo. Buprenorphine 251-264 opioid receptor, mu 1 Mus musculus 105-117